We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ALLE:NYSEAllegion plc Analysis

Data as of 2026-08-16 - not real-time

$164.78

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

The moving-average structure behind Allegion plc is neutral at $164.78, with no clear ordering between short and long averages. Over a rolling month the price has gained 17.8%. Momentum indicators put RSI at 67.3 (approaching overbought) with MACD reading bullish. Price has been bracketed by support at $134.63 and resistance at $170.87.
The shares look fair, trading on 21.7 times earnings below a sector average of 30.9. Sell-side targets cluster 6.0% above the current quote. Revenue is growing at 12.7% on a 15.4% profit margin. The 1.29% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 36.7%, a beta of 0.56 and a maximum drawdown of 30.1%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Short, medium and long-term reads agree on buy, with conviction of 6/10.

Top Market Events

Low-Double Digit Revenue Growth, High-Teens EPS Growth; Raising Full-Year 2026 Outlook Quarterly Financial Highlights...Low-Double Digit Revenue Growth, High-Teens EPS Growth; Raising Full-Year 2026 Outlook Quarterly Financial Highlights...Allegion PLC ALLE reports robust performance in the Americas, raises full-year revenue and EPS outlook, despite...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • Trading above the 200-day average of 151.60
  • MACD momentum is positive
  • 30-day price change of +17.8%

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 21.7 versus sector average of 30.9
  • Trading above the 200-day average of 151.60
  • Analyst targets imply +6.0% versus the current price

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 21.7 versus sector average of 30.9
  • Analyst targets imply +6.0% versus the current price
  • Profit margin of 15.4% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth12.70%
Profit Margin15.36%
P/E Ratio21.7
ROE33.73%
ROA11.03%
Debt/Equity104.89
P/B Ratio6.6
Op. Cash Flow$769.3M
Free Cash Flow$484.4M
Industry P/E30.9

Technical Analysis

TrendNeutral
RSI67.3
Support$134.63
Resistance$170.87
MA 20$157.43
MA 50$143.85
MA 200$151.60
MACDBullish
VolumeDecreasing
Fear & Greed Index95.98

Valuation

Fair Value$102.63
Target Price$174.64
Upside/Downside5.98%
GradeFair
TypeBlend
Dividend Yield1.29%

Risk Assessment

Beta0.56
Volatility36.71%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.